EMA Authorised: Ganfort (bimatoprost;timolol) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Ganfort, a combination of bimatoprost and timolol, for glaucoma (open-angle) and ocular hypertension in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• Ganfort (bimatoprost; timolol)

Snippet

Status: Authorised. Therapeutic area: Glaucoma, Open-Angle;Ocular Hypertension. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 15/11/2024